Septerna Inc SEPN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $34.36
- Day Range
- $33.54–35.37
- 52-Week Range
- $10.62–38.04
- Bid/Ask
- $24.00 / $39.95
- Shares Outstanding
- 45.08M
- Market Cap
- $1.56B
- Volume/Avg
- 650,791 / 418,137
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 21.25
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- < 0.01%
Company Profile
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 130
- Website
- https://www.septerna.com
Valuation
|
Metric
|
SEPN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.10 |
Price/Sales | 21.25 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SEPN
|
|---|---|
Quick Ratio | 4.63 |
Current Ratio | 4.71 |
Interest Coverage | — |
Quick Ratio
SEPN
Profitability
|
Metric
|
SEPN
|
|---|---|
Return on Assets (Normalized) | −6.80% |
Return on Equity (Normalized) | −9.25% |
Return on Invested Capital (Normalized) | −12.58% |
Return on Assets
SEPN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!PrvkMs | LOCK|@b!d | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#%$N@d | LOCK|y%!!> | $70B | |||
| argenx SE ADR
ARGX
| LOCK|<VHFp% | LOCK|sKJ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|bk@<$$y | LOCK|M@<!# | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&Z$y@Kd | LOCK|B# | $36B | |||
| Moderna Inc
MRNA
| LOCK|^y&%Q$^ | LOCK|B# | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%Q>JXK<& | LOCK|Q@SC! | $25B | |||
| Incyte Corp
INCY
| LOCK|Lg$@MzQ | LOCK|t! | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|qf^K?< | LOCK|V$ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|fp@rD%< | LOCK|@r | $16B |
United States